Nick Corriveau-Lecavalier PhD, LP

Brain implant lets man 'experience joy' for the first time in decades A device that has been likened to a pacemaker for the brain has given a man with severe depression great relief

A man who had severe depression for more than 30 years has "experienced joy" after undergoing bespoke brain stimulation.

Great line of speakers: @relajoie.bsky.social on behalf of G Rabinovici (USCF)
Jenny Whitwell (Mayo)
@neguine.bsky.social (Harvard)
Paul Aisen (USC)
Chukwuanugo Ogbuagu (NAUTH-USCF)

Chaired by @rikossenkoppele.bsky.social (Lund-Amsterdam UMC) and Rema Raman (UCSD)

For those attending #AAIC25, please consider our session "Improving Clinical Trials for Atypical Alzheimer’s Disease: A Call to Action" on Tuesday July 29th at 2PM!

Our team had worked relentlessly over the past years to make this tool, StateViewer, come to life and available to all neurologists across the Mayo Clinic Entreprise.

A great example of ethical AI use to enhance decision-making in real-life clinical scenarios.

I would say this is not the norm/expected but I may be wrong. They may also think your first name is Maria and last name Natasha :)

Does Death Have to Be a Death Sentence? (Update) - Freakonomics Does Death Have to Be a Death Sentence? (Update) - Freakonomics

Many clinicians are uncomfortable talking about death. We far too often over-treat illness at all cost, losing sight of what truly matters - quality of life. Excellent episode about death, and how to approach this topic with patients and loved ones: freakonomics.com/podcast/does...

📆 Mark your calendars for #AAIC25!

Do not miss this multidisciplinary and exciting perspective session on clinical trials for #AtypicalAD on July 29!

@rikossenkoppele.bsky.social @neusfalgas.bsky.social @corriveaunick.bsky.social @neguine.bsky.social @istaart.bsky.social

YouTube video by Neurology Journal Understanding Blood-Based Biomarkers in Alzheimer Disease

After an “update in cognitive & behavioral neurology” talk at AAN, I was asked to chat on the Neurology podcast (also no bsky but my request to change that has been noted!) about some of the content. We focused on plasma biomarkers. Still can’t listen to myself lol.

youtu.be/7wWOrZenplQ?...

@davidjonesbrain.bsky.social

YouTube video by SiliconANGLE theCUBE Gopal Srinivasan, Deloitte Consulting LLP & Dr. David Jones, Mayo Clinic | Google Cloud Next 2025

🚨 Video alert: I was able to share our @mayoclinic.org work on #NeuroAI at #GoogleCloudNext, including how we hope to scale expert interpretation of brain scans to improve dementia care.

🧠 Watch here: youtu.be/lJ1SVeeFWZQ?...

#DigitalHealth #AI #endalz

This patient was featured in all the LATE papers as a "pure LATE-NC" only to find out later that LATE was not the only driver...

Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease Abstract. Dysexecutive Alzheimer’s disease (dAD) manifests as a progressive dysexecutive syndrome without prominent behavioral features, and previous studi

Different systems. Patients with left-sided working memory system degeneration can exhibit language difficulties as a downstream effect of executiv dysfunction. Somewhat overlapping yet distinct degeneration pattern than in canonical PPA syndromes like logopenic PPA. academic.oup.com/cercor/artic...

Why academia is sleepwalking into self-destruction. My editorial @brain1878.bsky.social If you agree with the sentiments please repost. It's important for all our sakes to stop the madness
academic.oup.com/brain/articl...

The one case featured across LATE-NC papers appeared to have multiple neuropathologies in the medial temporal lobe at autopsy. Is pure LATE-NC a real thing? This is why we framed this syndrome as a limbic degeneration problem that is agnostic to underlying pathology academic.oup.com/braincomms/a...

If you are at #INS please stop by the non-AD session at 10:45 on Saturday to hear my talk about the clinical syndrome associated with limbic degeneration in old age!

I meant overstate, obviously.

Can't understate the importance of this paper by Deepti Putcha & LEADS...

EOAD is not an "earlier" amnestic phenotype. It's a fundamentally different disease. It's about time dysexecutive phenotypes receive the recognition they deserve.

alzres.biomedcentral.com/articles/10....

Excited to be chairing a new Stanford faculty search in Neurology. We are looking for MD and MD/PhD physician-scientists who have a strong research program (wet lab or dry lab) and who are also excellent clinicians. Please spread the word. Here's the link to the job posting:
lnkd.in/d6REUGfM

K99/R00 proposal is DONE. Can't understate how stressful this process was. Fingers crossed 🤞🏻

Good to know! Licensed Practitioner. Recently (and finally) obtained my license to independently practice neuropsych in the US

Yeah PET PIB and AV1451 tau off the charts. FDG was severe, so was her neuropsych. With teenagers at home 😞. I hope we find a way to help them. Clinical trials tailored to these populations are needed

Very heartbreaking. Youngest I have seen is 42 (sporadic)

Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes We present a retrospective case series of 55 individuals presenting with a progressive dysexecutive syndrome with biomarker evidence of Alzheimer’s disease

Large-scale studies often report findings about what seems to be an unusual "young-onset, aggressive" subtype of AD. Clinically we call this dysexecutive AD. We clearly define the distinct clinical and biological features of this AD variant here --> academic.oup.com/braincomms/a...

Excited to collaborate on this NIH-funded project on rapidly progressive dementias.

Great Friday ahead 🫠

Let me guess - NPH?

I am officially seeking a postdoc to work with us on software development for de-facing and PET quantification. Please pass along to any eligible candidates you may know. jobs.mayoclinic.org/job/rocheste...

(I know I am preaching to the choir here, just writing that in the hope that others may read 😊)

Amyloid/tau PET/plasma do not answer the same question as a mesure of functional anatomy. It only tells us if amyloid/tau are present. It says nothing about whether they are relevant to clinical presentation and copathologies. Stroke/DLB/FTD/PD + positive plasma =/= not necessarily AD!